CANF : Summary for Can-Fite Biopharma Ltd Sponsore - Yahoo Finance

U.S. Markets closed

Can-Fite BioPharma Ltd. (CANF)


NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
1.89+0.02 (+1.07%)
At close: 3:56PM EDT
People also watch
VBLTWGBSCNATBLRXAQXP
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.87
Open1.90
Bid0.00 x
Ask0.00 x
Day's Range1.87 - 1.96
52 Week Range1.74 - 3.59
Volume24,891
Avg. Volume107,201
Market Cap30.55M
Beta0.63
PE Ratio (TTM)-5.25
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire26 days ago

    New Preclinical Data Show Can-Fite's Namodenoson (CF102) Prevents Progression of Liver Fibrosis

    PETACH TIKVA, Israel, Feb. 28, 2017 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced new data that show its liver disease drug candidate Namodenoson (CF102) prevented liver (hepatic) fibrosis progression in preclinical studies. "These latest study results add to the growing body of data that demonstrate Namodenoson's potential efficacy in combating non-alcoholic fatty liver disease (NAFLD), the precursor to non-alcoholic steatohepatitis (NASH), indications for which there is currently no FDA approved drug. Liver fibrosis is the excessive accumulation of scar tissue resulting from ongoing inflammation.

  • Zacks Small Cap Researchlast month

    CANF: Ready to Start Two Phase III Trials in 2017

    On Feb. 8, 2017, Can-Fite (CANF) announced through a news release that the Company is ready to commence patient enrollment in the 2Q17 in its global Phase III trial of its lead drug candidate Piclidenoson (CF101) as a first line treatment for rheumatoid arthritis (RA). The EMA suggested Piclidenoson should be developed as an alternative to MTX, the most widely prescribed rheumatoid arthritis drug in the world. The EMA further suggested that this pivotal Phase III study will serve as the first of two pivotal studies required for drug approval.

  • PR Newswire2 months ago

    Can-Fite Gears Up for ACRobat, its Phase III Trial of Piclidenoson in Rheumatoid Arthritis

    PETACH TIKVA, Israel, Feb. 8, 2017 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today the Company is ready to commence patient enrollment in the second quarter of 2017 in its global Phase III trial of its lead drug candidate Piclidenoson as a first line treatment for rheumatoid arthritis. The required supply of Piclidenoson has already been manufactured and paid. Piclidenoson is being developed as a first line therapy and replacement for the current standard of care, Methotrexate (MTX), the most widely used drug for rheumatoid arthritis.